ATE256460T1 - Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler - Google Patents

Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler

Info

Publication number
ATE256460T1
ATE256460T1 AT98902381T AT98902381T ATE256460T1 AT E256460 T1 ATE256460 T1 AT E256460T1 AT 98902381 T AT98902381 T AT 98902381T AT 98902381 T AT98902381 T AT 98902381T AT E256460 T1 ATE256460 T1 AT E256460T1
Authority
AT
Austria
Prior art keywords
preparation
nasal administration
zonula occludens
vibrio cholera
administration containing
Prior art date
Application number
AT98902381T
Other languages
German (de)
English (en)
Inventor
Alessio Fasano
Teresa Demagistris
Sergio Uzzau
Rino Rappuoli
Original Assignee
Univ Maryland
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland, Chiron Srl filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE256460T1 publication Critical patent/ATE256460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98902381T 1997-01-09 1998-01-09 Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler ATE256460T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/781,057 US5908825A (en) 1997-01-09 1997-01-09 Dosage composition for nasal delivery and method of use of the same
PCT/US1998/000019 WO1998030211A1 (en) 1997-01-09 1998-01-09 Dosage composition for nasal delivery and method of use of the same

Publications (1)

Publication Number Publication Date
ATE256460T1 true ATE256460T1 (de) 2004-01-15

Family

ID=25121537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98902381T ATE256460T1 (de) 1997-01-09 1998-01-09 Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler

Country Status (9)

Country Link
US (1) US5908825A (https=)
EP (1) EP1028715B1 (https=)
JP (2) JP2001524940A (https=)
AT (1) ATE256460T1 (https=)
AU (1) AU5906398A (https=)
CA (1) CA2277824C (https=)
DE (1) DE69820671T2 (https=)
ES (1) ES2213267T3 (https=)
WO (1) WO1998030211A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
DE69716741T2 (de) * 1996-01-25 2003-06-12 Profylakse Aps, Odense Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
AU2002238106A1 (en) * 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
WO2004005324A2 (en) * 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
EP1648917A4 (en) * 2003-07-15 2008-11-12 Univ Maryland AGONISTPOLYPEPTIDE OF THE RECEPTOR FOR ZOT AND ZONULIN
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
DE10351778A1 (de) 2003-11-06 2005-06-09 Daimlerchrysler Ag Verfahren zur Korrespondenzanalyse in Bilddatensätzen
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
TW200637573A (en) * 2005-01-14 2006-11-01 Univ Maryland Peptide for delivery of mucosal vaccines
AR057058A1 (es) * 2005-06-09 2007-11-14 Alba Therapeutics Corp Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
ES2459018T3 (es) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
EP2004633A4 (en) * 2006-03-30 2009-08-26 Palatin Technologies Inc LINEAR NATRIURETIC PEPTIDE CONSTRUCTS
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
CA2647143A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
ES2628077T3 (es) 2009-02-27 2017-08-01 Pari GmbH Spezialisten für effektive Inhalation Dispositivo de inhalación de aerosol
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
EP2380618A1 (en) * 2010-04-26 2011-10-26 PARI Pharma GmbH Operating method for an aerosol delivery device and aerosol delivery device
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
MX365383B (es) 2014-03-14 2019-05-31 Opiant Pharmaceuticals Inc Medicamentos de administracion nasal y metodos para su uso.
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US10351599B2 (en) 2014-09-19 2019-07-16 Tensive Controls, Inc. Anti-microbial peptides
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470729A (en) * 1983-03-04 1995-11-28 University Of Maryland At Baltimore Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Also Published As

Publication number Publication date
EP1028715A4 (en) 2001-10-10
ES2213267T3 (es) 2004-08-16
EP1028715A1 (en) 2000-08-23
DE69820671T2 (de) 2004-09-30
CA2277824C (en) 2006-11-07
DE69820671D1 (de) 2004-01-29
CA2277824A1 (en) 1998-07-16
EP1028715B1 (en) 2003-12-17
AU5906398A (en) 1998-08-03
JP2006028199A (ja) 2006-02-02
JP2001524940A (ja) 2001-12-04
US5908825A (en) 1999-06-01
WO1998030211A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE69820671D1 (de) Zubereitung zur nasalen verabreichung enthaltend vibrio cholera zonula occludens toxin als absorptionsvermittler
DE69627147D1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
AU1534699A (en) Osmotic dosage form comprising first and second coats
GEP20053602B (en) Aripiprazole for Oral Administration
NO2016013I1 (no) Buprenorfin; 21-syklopropyl-7µ-[(S)-1-hydroksy-1,2,3-trimetylpropyl]-6,14-endoetano-6,7,8,14-tetrahydrooripavin
DE69940674D1 (de) Orale verabreichung von adenosin analogen
PL371736A1 (en) Method for administering glp-1 molecules
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
DE60019334D1 (de) Antivirale arznei
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
ATE243196T1 (de) Piperidine und pyrrolidine
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
TW261615B (https=)
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
MXPA04001912A (es) Aminobenzofenonas novedosas.
AU3885799A (en) Antidepressant therapy
ATE261732T1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DK1144420T3 (da) Sulfaterede phosphatidylinositoler, fremgangsmåde til fremstilling heraf og anvendelser heraf
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
EP1110547A3 (en) Helium and neon as means delivering drug in inhaler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties